Related Experiment Video
Updated: Jun 20, 2026

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
Interleukin-6 transcripts up-regulation in lymph nodes from unicentric and multicentric Castleman disease
Marco Lucioni1,2, Gaia Morello3, Caterina Cristinelli1
1Department of Molecular Medicine University of Pavia Pavia Italy.
Insights
Castleman disease (CD) involves elevated Interleukin-6 (IL-6) in lymph nodes. Endothelial cells are identified as a key source of this IL-6 production in CD patients.
Area of Science:
- Hematology
- Immunology
- Pathology
Background:
- Castleman disease (CD) is a group of lymphoproliferative disorders with varied symptoms.
- Interleukin-6 (IL-6) is a key cytokine implicated in CD's inflammatory processes.
- The cellular origin of IL-6 in CD's microenvironment remains unclear.
Purpose of the Study:
- To investigate the cellular source of IL-6 in Castleman disease lymph nodes.
- To quantify IL-6 expression across different CD subtypes and controls.
Main Methods:
- RNAscope analysis and dual in situ hybridization/immunohistochemistry were used.
- Five nodal CD cases (UCD, iMCD, HHV8+ MCD, HIV+ HHV8+ MCD) and a control were analyzed.
- Quantitative mRNA analysis was performed using HISTOQUANT software.
Main Results:
- Increased IL-6 expression was observed in all CD lymph nodes.
- HHV8+ cases showed the highest IL-6 levels, with significant differences compared to controls.
- IL-6 was consistently overexpressed in CD31-positive endothelial cells in all tested CD cases.
Conclusions:
- Endothelial cells are likely a major source of IL-6 in the nodal microenvironment of CD.
- A trend of increased IL-6 was noted in UCD and iMCD, while HHV8+ MCD showed significant upregulation.
- Findings highlight the role of endothelial IL-6 in CD pathogenesis.
Introduction:
Castleman disease (CD) represents a spectrum of heterogeneous lymphoproliferative disorders sharing peculiar histopathological features, clinically subdivided into unicentric CD (UCD) and multicentric CD (MCD) and presenting with variable inflammatory symptoms. Interleukin (IL)-6 and other cytokines play a major role in mediating CD inflammatory manifestations. Although the local microenvironment seems to be among the major sources of hypercytokinemia, the precise cellular origin of IL-6 production in CD is still debated.
Methods:
A series of five nodal CD of different subtypes (one UCD, two idiopathic MCDs [iMCDs], one HIV-negative human herpesvirus 8 (HHV8)-associated MCD, and one HIV-positive HHV8-associated MCD) and a non-CD reactive control were tested using RNAscope analysis and a dual in situ hybridization (ISH)/immunohistochemistry technique, in order to quantify IL-6 expression and its spatial distribution. Quantitative analyses of in situ mRNA were performed on digitalized slides using the HISTOQUANT software (3DHISTECH) and differences between cases were evaluated by the Kruskal-Wallis test.
Results:
RNA-ISH documented increased IL-6 expression in all CD lymph nodes, independently from clinical and pathological subtypes, however, the highest levels were found in HHV8+ cases and statistically significant differences in IL-6 expression were found only between HHV8+ MCD and control case. Dual RNA-ISH for IL6 coupled with immunohistochemistry analysis showed that IL-6 was overexpressed in CD31-positive endothelial cells in 5/5 CD tested cases but not in the control case.
Conclusion:
Our findings suggest that nodal IL-6 expression seems to be significantly upregulated in HHV8+ MCD, but a trend toward increased nodal IL-6 expression was noticed also in UCD and iMCD-not otherwise specified. CD31+ endothelial cells probably represent one of the major sources of IL-6 production in the nodal microenvironment.
More Related Videos
08:30Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
Published on: May 10, 2022
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024